From Vision to Action

«To engage SILAB in socially committed action while confirming its scientific culture, fundamental values and humanism – it is for these reasons that I decided on this creation» Jean PAUFIQUE.

The aim of the SILAB - Jean PAUFIQUE Corporate Foundation is to provide active and constant support for Fundamental and applied Research dedicated to the diagnosis, prognosis and treatment of skin pathologies, particularly skin cancer.

Professors Philippe HUMBERT and Christophe BEDANE, opinion leaders in the domain of Dermatological Research, have joined the Governing Body of the Corporate Foundation. They make an essential contribution to the corporate approach based on shared values: a passion for Research and support for young talent.


2019 prize-winner: Marine CORDONNIER

Marine CORDONNIER Marine CORDONNIER was nominated the 12th prize winner of the SILAB - Jean Paufique Corporate Foundation. Her EXOMEL project is dedicated to “understanding, treating and monitoring melanoma by studying exosomes”. The studies are conducted in the Lipids, Nutrition, and Cancer Center - LNC - INSERM UMR 866 Faculty of Medicine of Dijon, under the supervision of Prof. Carmen GARRIDO, Director of the Research Center and Head of the heat shock protein (HSP)-Pathies” team and Dr Jessica GOBBO. The goal of this project is to evaluate in vivo the efficacy of a combination of treatments aiming both at inhibiting the immunosuppression undertaken by the immune system and at preventing the release of carcinoma cells by this latter. The second aim of this research work consists in the assessment of the potential use of plasma exosomes as biomarkers for predicting the response to the immunotherapeutic treatments in patients suffering from melanoma. As a result, the objective of this innovative project is to increase the anti-tumor efficacy of immunotherapies on the one hand and to improve the selection of the most suitable patients to benefit from this kind of treatment on the other hand, in order to optimize patient care towards a more personalized medicine.